On Nov. 24, 2020, RELIEF THERAPEUTICS announced that more than 175 patients with Critical COVID-19 and Respiratory Failure who also have a severe comorbidity had been entered into an Expanded Access Protocol (EAP) with RLF-100 in the U.S.

In the EAP, no drug-related Serious Adverse Events were reported to date among these patients nor the 160 patients randomized to RLF-100(TM) vs. placebo in the U.S. phase 2b/3 clinical trial.